These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 27029709)
1. Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity. Koehler M; Donnelly ET; Kalanovic D; Dagher R; Rothenberg ML Ann Oncol; 2016 Jul; 27(7):1342-8. PubMed ID: 27029709 [No Abstract] [Full Text] [Related]
2. Leveraging electronic health record data for pragmatic randomized trials. Roe MT Clin Trials; 2020 Aug; 17(4):368-369. PubMed ID: 32668979 [No Abstract] [Full Text] [Related]
3. Gold standard or wrong standard? Oldham R; Dillman R Cancer Biother Radiopharm; 2004 Jun; 19(3):271-2. PubMed ID: 15285873 [No Abstract] [Full Text] [Related]
4. Palbociclib (Ibrance) for metastatic breast cancer. Med Lett Drugs Ther; 2015 Aug; 57(1475):115-6. PubMed ID: 26262882 [No Abstract] [Full Text] [Related]
5. Explanatory trials versus pragmatic trials. Sedgwick P BMJ; 2014 Nov; 349():g6694. PubMed ID: 25395503 [No Abstract] [Full Text] [Related]
6. Challenges ahead for companion diagnostics. Schmidt C J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588 [No Abstract] [Full Text] [Related]
13. Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. Anstrom KJ; Noth I; Flaherty KR; Edwards RH; Albright J; Baucom A; Brooks M; Clark AB; Clausen ES; Durheim MT; Kim DY; Kirchner J; Oldham JM; Snyder LD; Wilson AM; Wisniewski SR; Yow E; Martinez FJ; Respir Res; 2020 Mar; 21(1):68. PubMed ID: 32164673 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of regorafenib in colorectal cancer and GIST. Waddell T; Cunningham D Lancet; 2013 Jan; 381(9863):273-5. PubMed ID: 23177516 [No Abstract] [Full Text] [Related]
15. Choice of control group in randomised trials of cancer medicine: are we testing trivialities? Tao D; Prasad V Lancet Oncol; 2018 Sep; 19(9):1150-1152. PubMed ID: 30191836 [No Abstract] [Full Text] [Related]
16. Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial. Hartman L; Bos R; Buttgereit F; Güler-Yuksel M; Ionescu R; Kok MR; Lems WF; Micaelo M; Opris-Belinski D; Pusztai A; Santos E; Da Silva J; Szekanecz Z; Zeiner K; Zhang D; Boers M Scand J Rheumatol; 2019 Jul; 48(4):340-341. PubMed ID: 31132016 [No Abstract] [Full Text] [Related]
17. Advances in the battle against lung tumour resistance. Furlow B Lancet Respir Med; 2014 May; 2(5):353. PubMed ID: 24963524 [No Abstract] [Full Text] [Related]
18. Crossover is not associated with faster trial accrual. Chen EY; Prasad V Ann Oncol; 2018 Mar; 29(3):776-777. PubMed ID: 29267893 [No Abstract] [Full Text] [Related]